Clinical trials: Respiratory Allergy
Asthma
Research in Severe Asthma (RISA) Trial
The purpose of this study is to evaluate the safety and efficacy of the Alair System for the treatment of severe refractory asthma.
- Trial name
- NCT00214539
- Testing
- Bronchial Thermoplasty with the Alair System, Control
- Volunteers
- 34 people
- Sponsor
- Boston Scientific Corporation
Asthma
An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication
An observational study to investigate how patients experience the ability to adjust their asthma maintenance medication according to instructions received from their physician.
- Trial name
- INVOLVE (NCT00577265)
- Volunteers
- healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
This is a pivotal, 12-month, randomized, sham controlled, parallel group, multicenter, double blind study with an allocation ratio of 1:1.
- Trial name
- CREON2000A (NCT02715375)
- Testing
- CREON2000A
- Where
- 8 sites in United States
- Volunteers
- 83 people
- Sponsor
- General Innovations and Goods, Inc.
Allergy Pollen
Microassay and Allergy Skin Prick Test Correlation Study
The purpose of this study is to evaluate the potential correlation of the results of allergen-specific skin prick tests (SPT) to that of allergen-specific microarray determination (microassay test).
- Trial name
- NCT03514303
- Testing
- Spiriplex Allergenex Microassay
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- United Allergy Services
Asthma
Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients
This clinical study evaluates the 12-week efficacy and safety of Epinephrine HFA Inhalation Aerosol HFA the proposed HFA formulation of metered dose inhaler (MDI) of Epinephrine, in comparison to a Placebo-HFA control MDI and the…
- Trial name
- NCT01357642
- Testing
- Epinephrine inhalation aerosol
- Where
- 33 sites in United States
- Volunteers
- 373 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Aspirin Exacerbated Respiratory Disease (AERD)
Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease
The primary objective of the study is to determine the safety of oral ifetroban compared to placebo as measured by a > 20% decrease in FEV1 compared to baseline following a dose of Investigational Medicinal Product (IMP) (Study…
- Trial name
- NCT02216357
- Testing
- Ifetroban, Oral Capsule
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Cumberland Pharmaceuticals
Asthma
Pharmacokinetic Clinical Study of CHF1535 NEXT DPI® Versus CHF1535 pMDI
The aim of this clinical study is to compare the lung exposure of the contents of the trial drug after administration of the fixed combination between beclomethasone and formoterol delivered via the new Chiesi dry powder inhaler…
- Trial name
- NCT01349257
- Testing
- BDP/Formoterol
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Study to Evaluate the Effectiveness of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model
The purpose of this study is to evaluate the allergen-induced late asthmatic response (LAR), as measured by maximal percent fall in forced expiratory volume in 1 second, in participants with stable mild atopic asthma after…
- Trial name
- NCT01241422
- Testing
- JNJ 40929837, Montelukast
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 22 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Asthma
A Study to Determine the Effect of Montelukast Sodium as an Episode Modifier in the Treatment of Infrequent Episodic Asthma in Children (0476-165)
A 53-week study to determine the effect of montelukast sodium when given to children (with infrequent episodic asthma) at the earliest symptoms of an acute episode of asthma.
- Trial name
- NCT00140881
- Testing
- MK0476; montelukast sodium
- Volunteers
- 220 people
- Sponsor
- Organon and Co
Asthma
Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients
The purpose of this study is to demonstrate that CHF 1535 NEXT DPI® is non-inferior to the corresponding dose of CHF 1535 pMDI and superior to marketed beclomethasone DPI 100 µg in terms of average pre-dose morning Peak…
- Trial name
- Neptune (NCT01345916)
- Testing
- CHF 1535 100/6 NEXT DPI® 2 months, CHF 1535 100/6 pMDI 2 months, BDP DPI 2 months
- Where
- Poland
- Volunteers
- 932 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma
This study is designed to compare the effectiveness and safety of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) or 200mcg Fluticasone Furoate…
- Trial name
- NCT01706198
- Testing
- fluticasone furoate + vilanterol, inhaled corticosteroid with or without a long acting beta2-agonist
- Where
- 180 sites in United Kingdom
- Volunteers
- 4,233 people
- Sponsor
- GlaxoSmithKline
Allergic Asthma
A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
This was a multicenter, randomized, double-blind, parallel-group, three-arm, placebo-controlled study designed to demonstrate the efficacy of two different formulations of omalizumab compared with placebo in reducing the airway…
- Trial name
- AQUA (NCT00434434)
- Testing
- omalizumab
- Volunteers
- 61 people
- Sponsor
- Genentech, Inc.
Asthma
Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma
Study of Daily Dosing with Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects with Asthma
- Trial name
- NCT00073814
- Testing
- Levalbuterol tartrate MDI, racemic albuterol MDI
- Where
- 45 sites in United States
- Volunteers
- 80 people
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma
AMG 761 in Adults With Asthma
The purpose of this study is to determine that no significant safety issues will be identified following a single dose of AMG 761 in asthma subjects that would preclude further development of AMG 761.
- Trial name
- NCT01514981
- Testing
- AMG 761
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Amgen
Asthma
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose…
- Trial name
- Levante (NCT06529419)
- Testing
- AZD8630, Inhaler
- Where
- 196 sites in United States, Argentina and 21 more
- Volunteers
- 537 people
- Sponsor
- AstraZeneca
Asthma
A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma
The primary objective of this study is to evaluate the safety and tolerability of escalating multiple SC doses of MEDI-528 in adult patients with mild persistent asthma.
- Trial name
- NCT00507130
- Testing
- MEDI528 0.3 mg/kg, MEDI528 1 mg/kg, MEDI528 3 mg/kg
- Where
- 9 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- MedImmune LLC
Rhinitis, Urticaria
Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability and clinical efficacy will be measured.
- Trial name
- Aerius (NCT00724698)
- Testing
- Desloratadine
- Volunteers
- 3,011 people
- Sponsor
- Organon and Co
Allergic Rhinitis, Allergic Rhinoconjunctivitis
PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis
The objective of the present study is to characterize the dose-response relationship of PURETHAL® Mites with a nasal provocation test in order to support the optimal dose in terms of clinical efficacy and safety.
- Trial name
- NCT01438463
- Testing
- PURETHAL Mites 6,667 AU/ml, PURETHAL Mites 20,000 AU/ml, PURETHAL Mites 50,000 AU/ml
- Where
- 35 sites in Austria, Belgium and 3 more
- Volunteers
- 290 people
- Sponsor
- HAL Allergy
Seasonal Allergic Rhinitis
Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults
The study included three phases: the treatment introduction period (4-7 days before randomization), the treatment period (14 days after randomization) and the follow-up period (7 days after the last dose).
- Trial name
- NCT06861101
- Testing
- JT002 Nasal spray
- Where
- 44 sites in China
- Volunteers
- 370 people
- Sponsor
- Shanghai JunTop Biosciences Co., LTD
Asthma
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma.
- Trial name
- NCT06977581
- Testing
- PF-07275315
- Where
- 137 sites in United States, Argentina and 13 more
- Volunteers
- 252 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.